HRP20200889T1 - Upotreba dugodjelujućih peptida glp-1 - Google Patents

Upotreba dugodjelujućih peptida glp-1 Download PDF

Info

Publication number
HRP20200889T1
HRP20200889T1 HRP20200889TT HRP20200889T HRP20200889T1 HR P20200889 T1 HRP20200889 T1 HR P20200889T1 HR P20200889T T HRP20200889T T HR P20200889TT HR P20200889 T HRP20200889 T HR P20200889T HR P20200889 T1 HRP20200889 T1 HR P20200889T1
Authority
HR
Croatia
Prior art keywords
preparation
accordance
glp
agonist
intended
Prior art date
Application number
HRP20200889TT
Other languages
English (en)
Croatian (hr)
Inventor
Christine Bjørn JENSEN
Mads Frederik RASMUSSEN
Milan Zdravkovic
Peter Kristensen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20200889T1 publication Critical patent/HRP20200889T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20200889TT 2012-07-01 2013-06-21 Upotreba dugodjelujućih peptida glp-1 HRP20200889T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
EP13737808.9A EP2866825B1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (1)

Publication Number Publication Date
HRP20200889T1 true HRP20200889T1 (hr) 2020-09-04

Family

ID=65858459

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20200889TT HRP20200889T1 (hr) 2012-07-01 2013-06-21 Upotreba dugodjelujućih peptida glp-1
HRP20251088TT HRP20251088T1 (hr) 2012-07-01 2013-06-21 Upotreba dugodjelujućih peptida glp‑1

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20251088TT HRP20251088T1 (hr) 2012-07-01 2013-06-21 Upotreba dugodjelujućih peptida glp‑1

Country Status (17)

Country Link
US (2) US9764003B2 (enExample)
EP (3) EP3689365B1 (enExample)
JP (1) JP6059802B2 (enExample)
AU (3) AU2013286177B2 (enExample)
BR (1) BR112014032938A2 (enExample)
CA (1) CA2877056A1 (enExample)
DK (1) DK2866825T3 (enExample)
ES (2) ES2796839T3 (enExample)
HR (2) HRP20200889T1 (enExample)
HU (1) HUE049152T2 (enExample)
MX (3) MX376058B (enExample)
PL (2) PL3689365T3 (enExample)
PT (1) PT2866825T (enExample)
RS (2) RS67258B1 (enExample)
RU (2) RU2657573C2 (enExample)
SI (1) SI2866825T1 (enExample)
WO (1) WO2014005858A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
DK2866825T3 (da) 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
US10543843B2 (en) * 2014-10-16 2020-01-28 Yanmar Co., Ltd. Work vehicle
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー／エス Ｇｌｐ−１組成物及びその使用
MA50358A (fr) * 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
EP3930753A4 (en) * 2019-02-26 2023-03-29 Twist Bioscience Corporation VARIANT NUCLEIC ACID LIBRARIES FOR GLP1 RECEPTOR
KR20220110731A (ko) * 2019-11-06 2022-08-09 노보 노르디스크 에이/에스 치매에서의 glp-1 수용체 작용제
KR20220119731A (ko) * 2019-12-30 2022-08-30 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 장기 지속형 glp-1 화합물
AU2021208601B2 (en) * 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
US20240285729A1 (en) * 2021-06-24 2024-08-29 Gila Therapeutics, Inc. Methods and kits for inducing satiety and treating metabolic disorders
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US20230150998A1 (en) 2021-09-27 2023-05-18 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CN115850438B (zh) * 2021-12-28 2023-05-12 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2025024455A1 (en) 2023-07-24 2025-01-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
LT2373681T (lt) 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
NZ594044A (en) * 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP2013514322A (ja) * 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
KR101819609B1 (ko) * 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
JP2014520159A (ja) * 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
DK2866825T3 (da) 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider

Also Published As

Publication number Publication date
PL3689365T3 (pl) 2025-11-12
AU2013286177A1 (en) 2015-01-15
RU2018117557A (ru) 2019-03-22
RS67258B1 (sr) 2025-10-31
US9764003B2 (en) 2017-09-19
US20150190474A1 (en) 2015-07-09
EP3689365C0 (en) 2025-08-06
US20180085435A1 (en) 2018-03-29
MX2019008148A (es) 2019-09-05
US10335462B2 (en) 2019-07-02
EP4406593A3 (en) 2024-10-23
HUE049152T2 (hu) 2020-09-28
PT2866825T (pt) 2020-07-15
EP3689365B1 (en) 2025-08-06
RU2657573C2 (ru) 2018-06-14
EP2866825A1 (en) 2015-05-06
PL2866825T3 (pl) 2021-02-22
DK2866825T3 (da) 2020-06-08
JP2015522573A (ja) 2015-08-06
MX2014014946A (es) 2015-04-08
BR112014032938A2 (pt) 2017-08-01
ES3041720T3 (en) 2025-11-14
JP6059802B2 (ja) 2017-01-11
EP2866825B1 (en) 2020-04-08
MX376058B (es) 2025-03-07
WO2014005858A1 (en) 2014-01-09
AU2020202573A1 (en) 2020-05-07
AU2020202573B2 (en) 2023-04-20
RU2015101826A (ru) 2016-08-20
AU2018202504B2 (en) 2020-05-07
MX366405B (es) 2019-07-08
RU2018117557A3 (enExample) 2021-08-20
EP4406593A2 (en) 2024-07-31
ES2796839T3 (es) 2020-11-30
SI2866825T1 (sl) 2020-07-31
MX2020010693A (es) 2020-11-06
HRP20251088T1 (hr) 2025-11-07
CA2877056A1 (en) 2014-01-09
AU2013286177B2 (en) 2018-04-26
RS60432B1 (sr) 2020-07-31
EP3689365A1 (en) 2020-08-05
AU2018202504A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
HRP20200889T1 (hr) Upotreba dugodjelujućih peptida glp-1
HK1215934A1 (zh) 肽治疗剂及其使用方法
JP2015517488A5 (enExample)
NZ732507A (en) Improved compositions for treating muscular dystrophy
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
HRP20240485T1 (hr) Pripravci glp-1 i njihova upotreba
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
IN2014CN02592A (enExample)
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
HRP20170358T1 (hr) Inhibitori histonskih demetilaza
HK1247835A1 (zh) 甲状旁腺功能减退症的治疗
RU2016119746A (ru) Стабильный состав инсулина глулизин
RU2019139886A (ru) Терапевтическое средство против дисфункции мейбомиевых желез
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
AR120290A1 (es) Una forma de dosificación parenteral estable de acetato de cetrorelix
HRP20201632T1 (hr) Režimi doziranja melflufena kod raka
ME02405B (me) Spojevi pirazola као inhibitori sglt1
HRP20201696T1 (hr) Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu
HRP20180316T1 (hr) Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala